Sağı solu bloke edip duracağımıza acaba destek mi versek kalp kasına ? Şu daha mantıklı geliyor. https://t.co/6YajYtStCg
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.
Mentions
Extended reach
Total likes
Video views
Mentions per month
Mar 2020 – Sep 2025Where it's discussed
-
X / Twitter203 posts
-
News26 articles
-
Facebook5 posts
-
YouTube4 videos
-
Blogs4 articles
AI synopsis
What people are saying
Many conversations delve into the findings of the VICTORIA trial, with discussions highlighting the reduced risk of cardiovascular death and hospitalization observed with Vericiguat. Phrases like 'game changer' and inquiries about its clinical applications reflect a strong interest, while some posts question the significance of the 10% risk reduction, indicating a mix of cautious optimism and deeper inquiry.
Many discussions reflect a general acceptance of Vericiguat’s benefits, although some express skepticism about its clinical significance.
The topic garners noticeable enthusiasm, showcasing a level of excitement regarding the new treatment.
While some posts provide critical insights, others demonstrate a basic understanding of the research without diving deeply into the implications.
A consensus exists that this publication could significantly influence treatment strategies for heart failure patients.
Abstract in brief
- Vericiguat, a new medication, was tested in a study involving over 5,000 patients with heart failure and reduced ejection fraction, who had recently been hospitalized or treated with diuretics.
- The study found that patients taking vericiguat experienced fewer primary outcome events (death from cardiovascular causes or first hospitalization for heart failure) compared to those on placebo, with a hazard ratio of 0.90 indicating a 10% reduced risk.
- Although vericiguat showed promise, the rates of serious side effects like symptomatic hypotension and syncope were similar to placebo, suggesting it could be a safe option for high-risk heart failure patients.
Top posts
Most liked on X and Bluesky(1)
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/umwPqPbOmb
An example for debating what degree of risk reduction could be considered clinically significant. Here is a 3.5% absolute risk reduction (from 38.5 to 35%). And if it was NASH? Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/TelsezpV6L
#Vericiguat in Patients with #HFrEF : not available in France despite the #ARR of the combined primary endpoint. #HF https://t.co/bNbsGXYlPr
ベルイシグアトの効果を示した試験VICTORIA trialはこちらになります。 https://t.co/yVxDTTJlBE
All mentions
Guidelines for Pharmacotherapy in Heart Failure Management
Learn about the optimal medication prescriptions for patients with HFrEF based on the 2021 ESC Guidelines. This video discusses vericiguat, a promising new medication shown to reduce cardiovascular events in high-risk…
Optimizing Pharmacotherapy for Heart Failure with Reduced Ejection Fraction
This video explores the optimal medication strategies for patients with heart failure and reduced ejection fraction, in accordance with the 2021 ESC Guidelines. It examines the efficacy of new treatments, including…
New Insights on Heart Failure Treatments and Guidelines Update
Innovations in HFREF Treatment: Vericiguat Insights from 2025 ESC
Prof. Dr. John McMurray discusses novel developments in heart failure with reduced ejection fraction (HFREF) treatment, focusing on vericiguat outcomes from the VICTOR study. The findings suggest a reduced risk of…
RT @PGYpharmacy: Academic activity
RT @PGYpharmacy: Academic activity
Academic activity
RT @SABOURETCardio: #Vericiguat in Patients with #HFrEF : not available in France despite the #ARR of the combined primary endpoint. #HF h…
RT @SABOURETCardio: #Vericiguat in Patients with #HFrEF : not available in France despite the #ARR of the combined primary endpoint. #HF h…
#Vericiguat in Patients with #HFrEF : not available in France despite the #ARR of the combined primary endpoint. #HF https://t.co/bNbsGXYlPr
RT @Ferhatarslandr: Sağı solu bloke edip duracağımıza acaba destek mi versek kalp kasına ? Şu daha mantıklı geliyor. https://t.co/6YajYtSt…
RT @Ferhatarslandr: Sağı solu bloke edip duracağımıza acaba destek mi versek kalp kasına ? Şu daha mantıklı geliyor. https://t.co/6YajYtSt…
RT @Ferhatarslandr: Sağı solu bloke edip duracağımıza acaba destek mi versek kalp kasına ? Şu daha mantıklı geliyor. https://t.co/6YajYtSt…
RT @Ferhatarslandr: Sağı solu bloke edip duracağımıza acaba destek mi versek kalp kasına ? Şu daha mantıklı geliyor. https://t.co/6YajYtSt…
RT @Ferhatarslandr: Sağı solu bloke edip duracağımıza acaba destek mi versek kalp kasına ? Şu daha mantıklı geliyor. https://t.co/6YajYtSt…
RT @Ferhatarslandr: Sağı solu bloke edip duracağımıza acaba destek mi versek kalp kasına ? Şu daha mantıklı geliyor. https://t.co/6YajYtSt…
RT @Ferhatarslandr: Sağı solu bloke edip duracağımıza acaba destek mi versek kalp kasına ? Şu daha mantıklı geliyor. https://t.co/6YajYtSt…
RT @Ferhatarslandr: Sağı solu bloke edip duracağımıza acaba destek mi versek kalp kasına ? Şu daha mantıklı geliyor. https://t.co/6YajYtSt…
RT @Ferhatarslandr: Sağı solu bloke edip duracağımıza acaba destek mi versek kalp kasına ? Şu daha mantıklı geliyor. https://t.co/6YajYtSt…
RT @Ferhatarslandr: Sağı solu bloke edip duracağımıza acaba destek mi versek kalp kasına ? Şu daha mantıklı geliyor. https://t.co/6YajYtSt…
RT @Ferhatarslandr: Sağı solu bloke edip duracağımıza acaba destek mi versek kalp kasına ? Şu daha mantıklı geliyor. https://t.co/6YajYtSt…
RT @Ferhatarslandr: Sağı solu bloke edip duracağımıza acaba destek mi versek kalp kasına ? Şu daha mantıklı geliyor. https://t.co/6YajYtSt…
RT @Ferhatarslandr: Sağı solu bloke edip duracağımıza acaba destek mi versek kalp kasına ? Şu daha mantıklı geliyor. https://t.co/6YajYtSt…
RT @Ferhatarslandr: Sağı solu bloke edip duracağımıza acaba destek mi versek kalp kasına ? Şu daha mantıklı geliyor. https://t.co/6YajYtSt…
Sağı solu bloke edip duracağımıza acaba destek mi versek kalp kasına ? Şu daha mantıklı geliyor. https://t.co/6YajYtStCg
RT @drhungo:
RT @drhungo:
RT @drhungo:
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction https://t.co/1LjftVDAcV
RT @secardiologia: Vericiguat es una nueva molécula para el tratamiento de IC crónica con FEVI<45%. Indicada en pacientes con alto riesgo d…
RT @secardiologia: Vericiguat es una nueva molécula para el tratamiento de IC crónica con FEVI<45%. Indicada en pacientes con alto riesgo d…
RT @secardiologia: Vericiguat es una nueva molécula para el tratamiento de IC crónica con FEVI<45%. Indicada en pacientes con alto riesgo d…
Vericiguat es una nueva molécula para el tratamiento de IC crónica con FEVI<45%. Indicada en pacientes con alto riesgo de descompensación, ha demostrado reducción de muerte cardiovascular y rehospitalizaciones #ClavesIC #eCardio23 https://t.co/behsq4o8kL https://t.co/61TpBNLTuw
@SaraMuhaisni @Banitoto Phase 3 study ( VICTORIA trial) was published in 2020 Real world data is needed! https://t.co/Z6QWmFx1d5
RT @AAlMohammad87: Interesting that the #TA731 intended by @NICEComms to look into the role of #Vericiguat in the treatment of chronic #HF…
RT @AAlMohammad87: Interesting that the #TA731 intended by @NICEComms to look into the role of #Vericiguat in the treatment of chronic #HF…
Interesting that the #TA731 intended by @NICEComms to look into the role of #Vericiguat in the treatment of chronic #HF was terminated pending further submissions. @BSHeartFailure @escardio @TheresaMcDonag3 @MarcoMetra #CardioTwitter #CardioEd @NEJM DOI: 10.1056/NEJMoa1915928
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction https://t.co/XD3pk8eXoo
RT @tororo__ph: https://t.co/hLaFljwMnR https://t.co/XM0wOuIsME
https://t.co/hLaFljwMnR https://t.co/XM0wOuIsME
ベリシグアトって心血管死+心不全入院をNNT 33程度で減らすけど死亡・心不全入院をそれぞれわけると有意差つかない、、、くらいの立ち位置の薬なのね。。 https://t.co/zjTOltDLGX
RT @cardiomet_CE: 43) Consider the #VICTORIA study: Vericiguat significantly ⬇️ annualized absolute rate of time to #HHF or #CVdeath by 4.2…
RT @cardiomet_CE: 45b) #vericiguat can be safely combined with other therapies to treat #HF and comorbidities
RT @cardiomet_CE: 45b) #vericiguat can be safely combined with other therapies to treat #HF and comorbidities
RT @cardiomet_CE: 43) Consider the #VICTORIA study: Vericiguat significantly ⬇️ annualized absolute rate of time to #HHF or #CVdeath by 4.2…
RT @cardiomet_CE: 45b) #vericiguat can be safely combined with other therapies to treat #HF and comorbidities
RT @cardiomet_CE: 43) Consider the #VICTORIA study: Vericiguat significantly ⬇️ annualized absolute rate of time to #HHF or #CVdeath by 4.2…
45b) #vericiguat can be safely combined with other therapies to treat #HF and comorbidities
43) Consider the #VICTORIA study: Vericiguat significantly ⬇️ annualized absolute rate of time to #HHF or #CVdeath by 4.2 events/100 patient-year #Vericiguat changes the disease trajectory by reducing recurrent HF #hospitalization
للاستزاده عن هذا الدواء ، مرفق لكم دراسة محكمة RCTs
RT @sarahhudsonuk: New drugs on the horizon for #HF: @lamcardio talked about the novel oral soluble guanylate cyclase stimulator vericiguat…
#079 Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction N Engl J Med 2020;382:1883-93. VICTORIA試験 ベルイシグアトは、プラセボと比較してHFrEF患者の心血管死と心不全入院の複合エンドポイントを改善させる
Vericiguat: @nejm https://t.co/fTM4dWEJjs https://t.co/Jrmv2qDXjt
Vericiguat en la reunión de hoy en @Sochicaroficial, exposición de @MirtaDiez4 y moderación de @douglasgreig Se expuso el estudio VICTORIA DOI: 10.1056/NEJMoa1915928 https://t.co/yOs1nk364y
Vericiguat en pacientes con insuficiencia cardíaca y fracción de eyección reducida https://t.co/hhgmN8EMSJ Entre los Pac con IC de alto riesgo, la incidencia de muerte por causas cardiovasculares u hospitalización por IC fue menor entre los que recibieron Vericiguat VS placebo.
Os dejamos aquí el
VICTORIA Trial https://t.co/RoezG00YZP
Vericiguat in patients with heart failure and reduced ejection fraction https://t.co/ki3exROvZs
RT @anudodejamd: What about Grp II PAH? ♦️Do: Rx #GDMT for #HFrEF & #HFPEF ♦️Don't: Rx with pulm vasodilators in pt w/ ⬆️ PCWP ♦️ conside…
What about Grp II PAH? ♦️Do: Rx #GDMT for #HFrEF & #HFPEF ♦️Don't: Rx with pulm vasodilators in pt w/ ⬆️ PCWP ♦️ consider vericiguat in selected pt w/ HFrEF https://t.co/KrakC92EV4 https://t.co/cOhHVC9ovM
RT @nebetake: ベルイシグアトの効果を示した試験VICTORIA trialはこちらになります。 https://t.co/yVxDTTJlBE
RT @nebetake: ベルイシグアトの効果を示した試験VICTORIA trialはこちらになります。 https://t.co/yVxDTTJlBE
いま、ゼンゼンさんに並びなび、多分あと3ロットぐらいの列。 承認となったベルイシグアトを読んでおこう。 (傍で処方が出るのを見るのはずっと先かな
ベルイシグアトの効果を示した試験VICTORIA trialはこちらになります。 https://t.co/yVxDTTJlBE
VICTORIA: The use of vericiguat, oral soluble guanylate cyclase stimulator in patients with heart failure was associated with reduced CV death and hospitalizations for HF #UMKCRCT https://t.co/VphG7qt7LY
Vericiguatもまた微妙な薬よね。 death from cardiovascular causes or first hospitalization for heart failure.▶ https://t.co/qQg8EjTuTJ change in the KCCQ PLS▶ https://t.co/mlRM9PcwZC
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction Read more - https://t.co/3RmUXb1x0i #metabolichealthdigest #hypertension #heartfailure #highbloodpressure #bloodpressure #bloodpressureproblems https://t.co/pA8Z256odn
¿Será que no son comparables por aquello del tratamiento actual? ¿Pero si son tan diferentes el tratamiento adjunto? https://t.co/C1oq5fBhNV
VICTORIA Trial Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction https://t.co/y1Gp8opnKy https://t.co/NvUTzYM0kU
RT @JuliaSellerm:
RT @JuliaSellerm:
RT @JuliaSellerm:
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction https://t.co/VVJFM4haJF
@geraniumlovefo1 これです! https://t.co/OxoBky0Wmz
Cerebral discussion during journal club today with Dr. Julio Nieto PGY3 on review of “Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction”. Well done Doc! https://t.co/pjuemCRHYI
https://t.co/8wx5ETAs9W
Estimulador de la guanilato ciclasa soluble en pacientes con falla cardiaca y fracción de eyección reducida ¿Realmente mejora la mortalidad por causas cardiovasculares? @JORARTU https://t.co/32D1xFok1N
https://t.co/C1oq5fBhNV
RT @sarahhudsonuk: New drugs on the horizon for #HF: @lamcardio talked about the novel oral soluble guanylate cyclase stimulator vericiguat…
New drugs on the horizon for #HF: @lamcardio talked about the novel oral soluble guanylate cyclase stimulator vericiguat and the VICTORIA trial - great potential, with ⬇️CV death/HF hospitalisations with an annual NNT of 24. https://t.co/ExInUzpi7z #ESCCongress #HF https://t.co/OUOVx4kqCc
RT @smexcardiologia: Aprende más al respecto en la siguiente liga: https://t.co/n3lBT7pFyY #SocMexCardio @ACMrevista @cardiodata @ANCAM_M…
RT @smexcardiologia: Aprende más al respecto en la siguiente liga: https://t.co/n3lBT7pFyY #SocMexCardio @ACMrevista @cardiodata @ANCAM_M…
Aprende más al respecto en la siguiente liga: https://t.co/n3lBT7pFyY #SocMexCardio @ACMrevista @cardiodata @ANCAM_MEXICO @rodrigogopar @mitrehit @LuisBaeza15 @GreciaRaymundo @drdargaray @aleglezl @daniieelg @MHMichel
RT @ChadSWeldy: Got to give Journal Club for @StanCVFellows with faculty discussants including @HeartBobH @EldrinL @Ron_Witteles @joshuawkn…
Got to give Journal Club for @StanCVFellows with faculty discussants including @HeartBobH @EldrinL @Ron_Witteles @joshuawknowles @euanashley and others and I dared to talk about oxidative stress and nitric oxide! Wonderful discussion about VICTORIA https://t.co/c3onW8lNIo
In patients with HFrEF: Add-on #vericiguat Death from cardiovascular causes occurred in 414 patients (16.4%) in the vericiguat group and in 441 patients (17.5%) in the placebo group (hazard ratio, 0.93). | NEJM https://t.co/Zqao4bMOYe https://t.co/hYKxBaQ0ru
RT @ken_korai: NEJMに出てましたけど、日本ではARNIもままならないまま世界で治療が進んでいきますね、、、 https://t.co/MU1pMj18pD リオシグアトと使い勝手は似たようなものなんですかねぇ??
NEJMに出てましたけど、日本ではARNIもままならないまま世界で治療が進んでいきますね、、、 https://t.co/MU1pMj18pD リオシグアトと使い勝手は似たようなものなんですかねぇ?? https://t.co/2mTrUCc4bG
Vericiguat In Patients With Heart Failure And Reduced Ejection Fraction #Cardiovasculardisease #Health #HeartFailure #Medicine #Research #study #Vericiguat https://t.co/vafr7hieVK
RT @geri_doc: Yet another NEJM CHF study with composite outcome of death or hospitalization. It is 2020. Why is this considered a NEJM w…
RT @j_alvarezgarcia: (1)
RT @j_alvarezgarcia: (1)
RT @j_alvarezgarcia: (1)
RT @j_alvarezgarcia: (1)
RT @j_alvarezgarcia: (1)
RT @j_alvarezgarcia: (1)
RT @j_alvarezgarcia: (1)
RT @j_alvarezgarcia: (1)
RT @j_alvarezgarcia: (1)
RT @j_alvarezgarcia: (1)
RT @j_alvarezgarcia: (1)
RT @j_alvarezgarcia: (1)
RT @j_alvarezgarcia: (1)
RT @geri_doc: Yet another NEJM CHF study with composite outcome of death or hospitalization. It is 2020. Why is this considered a NEJM w…
RT @j_alvarezgarcia: (1)
RT @j_alvarezgarcia: (1)
RT @j_alvarezgarcia: (1)
RT @j_alvarezgarcia: (1)
(1)
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. https://t.co/xwr845ifBG https://t.co/7zPfZMnQLE
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/T2AUmMBce5 https://t.co/vbOy0d3Los
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/Csd7SL0gXr
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/MZyPeC1jWP
RT @geri_doc: Yet another NEJM CHF study with composite outcome of death or hospitalization. It is 2020. Why is this considered a NEJM w…
https://t.co/FQ3uh1CgGV Me gustan mucho estos vídeos informativos sobre estudios, pero nunca pueden reemplazar la revisión crítica de un artículo. https://t.co/PNyf9ApM43
RT @geri_doc: Yet another NEJM CHF study with composite outcome of death or hospitalization. It is 2020. Why is this considered a NEJM w…
RT @geri_doc: Yet another NEJM CHF study with composite outcome of death or hospitalization. It is 2020. Why is this considered a NEJM w…
RT @geri_doc: Yet another NEJM CHF study with composite outcome of death or hospitalization. It is 2020. Why is this considered a NEJM w…
RT @geri_doc: Yet another NEJM CHF study with composite outcome of death or hospitalization. It is 2020. Why is this considered a NEJM w…
RT @geri_doc: Yet another NEJM CHF study with composite outcome of death or hospitalization. It is 2020. Why is this considered a NEJM w…
RT @geri_doc: Yet another NEJM CHF study with composite outcome of death or hospitalization. It is 2020. Why is this considered a NEJM w…
RT @geri_doc: Yet another NEJM CHF study with composite outcome of death or hospitalization. It is 2020. Why is this considered a NEJM w…
RT @geri_doc: Yet another NEJM CHF study with composite outcome of death or hospitalization. It is 2020. Why is this considered a NEJM w…
RT @geri_doc: Yet another NEJM CHF study with composite outcome of death or hospitalization. It is 2020. Why is this considered a NEJM w…
RT @geri_doc: Yet another NEJM CHF study with composite outcome of death or hospitalization. It is 2020. Why is this considered a NEJM w…
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction Just read the VICTORIA trial . Looking at the HR and CI I am not that impressed . Also how are we going to apply this now with the DAPA-HF data Thoughts ?
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM って事はアデンパスも心不全に効果あるのかな? #NEJM https://t.co/IHYM5Uaktg
RT @jaumebosch9: An example for debating what degree of risk reduction could be considered clinically significant. Here is a 3.5% absolute…
RT @jaumebosch9: An example for debating what degree of risk reduction could be considered clinically significant. Here is a 3.5% absolute…
An example for debating what degree of risk reduction could be considered clinically significant. Here is a 3.5% absolute risk reduction (from 38.5 to 35%). And if it was NASH? Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/TelsezpV6L
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/53xPhods6C
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/s5Lq6zSfZj
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/ckpbqRSXPb
Topic Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
HFrEFは次々とエビデンスが集積されますよね。可溶性グアニル酸シクラーゼ刺激薬であるvericiguatがプラセボと比較して心血管死/心不全入院を減少。 #vericiguat #心不全 Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/SRSWzRKcqR
A new drug for heart failure! A guanylate cyclase stimulator - thought that was an ingredient in Red Bull. Bit busy right now. See you in 6 months. BW Sean https://t.co/0sMfYOnYDr
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM #meded #foamed @cardionerds #heartfailure https://t.co/gIfZqJUzYo
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/wHNj7DxZFt
RT @ernestocardio: Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/ARGGoY5WX0 @mencardio @torre…
RT @ernestocardio: Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/ARGGoY5WX0 @mencardio @torre…
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. https://t.co/nIhbWxkc9c
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM. Will this work similar to ARNI therapy as ANP is thought to work through cGMP. Will be interesting to compare. Also to look at renal outcomes! https://t.co/Ex6d2AXNkb
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. https://t.co/5r1x9MnTWR
RT @gcfmd: Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/umwPqPbOmb
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. https://t.co/szcOi0HUIZ
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. https://t.co/XQSKKwcNYP
RT @ernestocardio: Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/ARGGoY5WX0 @mencardio @torre…
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/Dwn3quMD6D
RT @gcfmd: Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/umwPqPbOmb
RT @JBauersachsMD: Significant reduction of CV death and #HF hospitalization by novel soluble guanylate Cyclase Stimulator: Vericiguat in P…
RT @Manugrillo2: Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/nQuYRuWfPr
RT @ernestocardio: Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/ARGGoY5WX0 @mencardio @torre…
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction – https://t.co/LR7Z1WJWXX https://t.co/rPipJAUwdc
RT @JBauersachsMD: Significant reduction of CV death and #HF hospitalization by novel soluble guanylate Cyclase Stimulator: Vericiguat in P…
RT @gcfmd: Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/umwPqPbOmb
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/PIOaUyat1J #acc2020
RT @gcfmd: Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/umwPqPbOmb
Interesting trial of an sGC stimulator in chronic HF with EF <45%. Modest reduction in HF hospitalization rate. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/Pr8lJ6EwIH
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/BwTClYKaZ2
RT @ernestocardio: Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/ARGGoY5WX0 @mencardio @torre…
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/ARGGoY5WX0 @mencardio @torresviera @igormorr @jstragazue @drjarayg @recetario1 @apoleo @Lguevaramath @DrPontecarlosi @emartinezgmg @mirecly2013 @jacardio @lugocastle @jpcostabel @ramicule
#VICTORIA trial full paper in @NEJM
RT @gcfmd: Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/umwPqPbOmb
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/GFfUGTGxB6
Interesting results, but only 60% on triple therapy? Be good learn more as to why... Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM #heartfailure https://t.co/N6FihqaRKv
RT @JBauersachsMD: Significant reduction of CV death and #HF hospitalization by novel soluble guanylate Cyclase Stimulator: Vericiguat in P…
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/i0azxi2ryK
RT @doctorchecho: Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/1lYyYwi19K
RT @gcfmd: Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/umwPqPbOmb
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/8bhhclm8Pk
RT @gcfmd: Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/umwPqPbOmb
RT @hect2701: Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM HR 0.90; 95% CI, 0.83 to 0.98; P=0.02; is th…
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/nQuYRuWfPr
RT @ethanjweiss: This feels sort of
RT @hect2701: Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM HR 0.90; 95% CI, 0.83 to 0.98; P=0.02; is th…
RT @doctorchecho: Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/1lYyYwi19K
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/SDV1RPD8pD
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/jgcZ0nlSyT
Significant reduction of CV death and #HF hospitalization by novel soluble guanylate Cyclase Stimulator: Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/K0trcZAkEy
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/Ravn5fKL3z
RT @gabrielsteg: Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/GA1rF1aXOi
RT @hect2701: Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM HR 0.90; 95% CI, 0.83 to 0.98; P=0.02; is th…
RT @gcfmd: Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/umwPqPbOmb
RT @rblument1: Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/1G6C4mVJW4
RT @gabrielsteg: Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/GA1rF1aXOi
RT @rblument1: Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/1G6C4mVJW4
RT @hect2701: Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM HR 0.90; 95% CI, 0.83 to 0.98; P=0.02; is th…
RT @gcfmd: Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/umwPqPbOmb
RT @gabrielsteg: Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/GA1rF1aXOi
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/GA1rF1aXOi
RT @gcfmd: Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/umwPqPbOmb
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/1G6C4mVJW4
RT @doctorchecho: Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/1lYyYwi19K
RT @doctorchecho: Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/1lYyYwi19K
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/1lYyYwi19K
This feels sort of
RT @gcfmd: Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/umwPqPbOmb
RT @hect2701: Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM HR 0.90; 95% CI, 0.83 to 0.98; P=0.02; is th…
RT @gcfmd: Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/umwPqPbOmb
RT @gcfmd: Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/umwPqPbOmb
RT @hect2701: Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM HR 0.90; 95% CI, 0.83 to 0.98; P=0.02; is th…
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM HR 0.90; 95% CI, 0.83 to 0.98; P=0.02; is this 10% reduction enough to add it to the HF portafolio? #ACC2020 #ACC20 https://t.co/yPNK1JAuVQ
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/umwPqPbOmb
Full paper now available on NEJM. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/8oSztRfSZj